{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 11 April 2007\line \line {\b Roche 
and Transgene enter partnership on therapeutic vaccines against HPV-mediated diseases} \line Roche 
to develop and commercialize products from Transgene\u8217?s programme\line \line Roche 
and Transgene announced today that they have entered into an exclusive worldwide collaboration agreement 
to develop and commercialize products from Transgene\u8217?s therapeutic vaccine program against Human Papilloma 
Virus-mediated diseases. The Human Papilloma Virus (HPV) is associated with the development of precancerous 
lesions and cancer of the cervix. The agreement includes Transgene\u8217?s lead therapeutic vaccine candidate 
TG 4001 (MVA-HPV-IL2), currently in clinical development to treat high grade cervical intraepithelial 
neoplasia (CIN2/3), a precancerous cervical abnormality which can lead to cervical cancer. Under the 
agreement, Roche will lead worldwide development and commercialization. TG 4001 has completed Phase 
II studies and is in planning for entry into Phase III studies.\line \line \u8216?Transgene 
is an ideal strategic fit for Roche, offering a differentiated approach to a precancerous condition 
with high unmet need,\u8217? said Peter Hug, Roche\u8217?s Global Head of Pharma Partnering. \u8216?Transgene\u8217?s expertise 
in viral vaccine therapeutics complements our core capabilities in oncology and virology drug development. 
In addition, as Roche is a leader in in vitro diagnostics with strong capabilities in HPV detection, 
our collaboration with Transgene has the potential to expand and evolve into an integrated personalized 
medicine approach. We look forward to working with Transgene on this program.\u8217?\line \line \u8216?We 
are delighted by Roche\u8217?s commitment to further develop our promising vaccine TG 4001 in the field of 
HPV-mediated diseases,\u8217? said Philippe Archinard, Chief Executive Officer of Transgene. \u8216?Roche has broad 
expertise and a leadership position in the development and marketing of first-in-class innovative therapies. 
This first strategic partnership is an acknowledgement of the validity of our technology and strategy. 
It is a considerable transforming event for Transgene that we anticipate will enable us to accelerate 
and broaden the development of our entire product portfolio.\u8217?\line \line {\b Terms 
of the Agreement} \line Roche will acquire an exclusive license for TG 4001 and further 
therapeutic vaccine development candidates resulting from the collaboration in HPV-mediated diseases, 
and will have exclusive worldwide commercialization rights. Roche will fund all future costs associated 
with the development of TG 4001 and will lead the Phase III studies.\line \line Transgene 
will receive 13 million Euros as an upfront payment and 10 million Euros as a near-term regulatory milestone 
payment related to planning the Phase III studies. Roche may pay Transgene up to 195 million Euros, 
upon the achievement of certain further development and sales-based events in various HPV-related indications. 
Transgene is also entitled to double-digit escalating royalties on sales once a product is marketed.\line \line Roche 
will hold all manufacturing rights but has agreed to allocate, on commercial terms, exclusive responsibility 
to Transgene for the clinical-trial supply of TG 4001 and additional HPV products, which may be developed 
in the future. This agreement will be extended to commercial-supply manufacturing for an initial period. 
\line \line {\b About TG 4001} \line TG 4001 therapeutic 
vaccine is designed to target HPV type 16 (HPV16), known to be a high risk factor for the development 
of precancerous cervical intraepithelial neoplasia and subsequently cervical cancer.\line \line TG 
4001 (MVA-HPV-IL2) is based on a non-propagative, highly attenuated vaccinia vector (MVA), which is 
engineered to express HPV16 antigens and an adjuvant. As an immunotherapy for women diagnosed with diseases 
caused by the HPV 16 infection, TG 4001 is designed to have a two-pronged anti-viral approach: to alert 
the immune system specifically to HPV16-infected cells that have started to undergo precancerous transformation 
(cells presenting the HPV16 E6 and E7 antigens) and to further stimulate the infection-clearing activity 
of the immune system through an adjuvant (interleukin 2). \line \line In Phase II 
clinical trials, TG 4001 demonstrated safety and promising clinical responses and efficacy in women 
with HPV16 CIN2/3. Results of a trial in France, announced last year, of 21 women with HPV16 CIN 2/3, 
showed promise as 10 women no longer had detectable levels of CIN2/3 six months after vaccination (disappearance 
of the precancerous lesions and no detectable HPV16 E6 / E7 mRNA). No serious side effects were observed. 
Sustainability of the response was assessed by an examination at Month 12 of the patients who did not 
undergo surgical excision of CIN lesions at Month 6. No CIN2/3 relapse nor any HPV16 persistence or 
re-infection were observed in these women. A placebo-controlled Phase III program is in planning to 
enrol an estimated 500 patients with CIN2/3 caused by HPV16. \line \line {\b About 
HPV-mediated diseases} \line HPV infection is recognized as the necessary cause of precancerous 
cervical lesions and cervical cancers and is the most common sexually transmitted disease affecting 
about 400 million women worldwide. Most infections are spontaneously eliminated in less than one year. 
In the remaining cases, persistent HPV infection can lead, after several years or decades, to precancerous 
lesions of the cervix - called cervical intraepithelial neoplasia of grades 2 and 3 (CIN 2/3) - and 
eventually to cervical cancer. Worldwide, new cases are reported at a yearly rate of around 1.4 million 
for CIN 2/3 and 500,000 for cervical cancer, of which approximately 50% are linked to HPV16. The HPV16 
genotype, along with HPV18, 31 and 33 genotypes, have the highest risk of transforming infected cervical 
cells into cancerous cells. \line \line Due to the wider use of HPV testing, HPV 
infection is being diagnosed in an increasing number of women, but no anti-viral treatment is currently 
available. Surgical resection, currently the only therapeutic solution, is highly effective but presents 
medical complications and relapses. Therefore, a therapeutic vaccine to clear precancerous lesions and 
the associated HPV infection could be an effective, non-invasive approach for the prevention of cervical 
cancer.\line \line Roche launched the Amplicor HPV Test and the Linear Array HPV 
Genotyping Test in Europe in 2004 and 2005 respectively. Both tests are currently under review by the 
US Food & Drug Administration (FDA) for approval to market the tests in the United States. The Amplicor 
HPV Test is designed to enable accurate detection of 13 high-risk HPV genotypes (including HPV16) in 
standard clinical samples. The Linear Array HPV Genotyping Test is designed to identify which of 13 
high-risk HPV genotypes are present in a sample. Studies worldwide have used the research prototype 
of the Roche Diagnostics Linear Array HPV Test to better understand HPV.\line \line {\b About 
Transgene} \line Transgene is a France-based biopharmaceutical company dedicated to the 
development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. 
The company has three compounds in Phase II trials and one compound in Phase I studies. Transgene has 
bio-manufacturing production capacities for viral-based vectors and technologies available for out-licensing. 
Additional information about Transgene is available on the Internet at www.transgene.fr (http://www.transgene.fr).\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused 
healthcare groups in the fields of pharmaceuticals and diagnostics. As the global leader in biotechnology, 
Roche contributes on a broad range of fronts to improving people\u8217?s health and quality of life by supplying 
innovative products and services for the early detection, prevention, diagnosis and treatment of diseases. 
Roche is the world leader in in-vitro diagnostics, the leading supplier of drugs for cancer and transplantation 
and a market leader in virology. It is also engaged in other important therapeutic areas including autoimmune, 
inflammatory and metabolic disease and diseases of the central nervous system. In 2006 sales by the 
Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales 
of 8.7 billion Swiss francs. Roche employs roughly 75,000 people worldwide and has R&D agreements 
and strategic alliances with numerous partners, including majority ownership interests in Genentech 
and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\line \par}\line \line {\b Additional 
information} \line - Roche Diganostics in Women\u8217?s Health \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}